

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Tankyrase TRF1-interacting ankyrin-related ADP-ribose polymerase (TNKS)	An SAR study identified TNKS inhibitors that could help treat cancer. Rational design studies led to a series of compounds that blocked two substrate-binding pockets formed by TNKS dimers. <i>In vitro</i> , the best of those compounds inhibited TNKS with an IC ₅₀ value of 8 nM and prevented wntless-type MMTV integration site (WNT) pathway signaling in cell culture. Next steps include designing and testing more biologically stable derivatives of high-affinity TNKS inhibitors. SciBX 6(5); doi:10.1038/scibx.2013.111 Published online Feb. 7, 2013	Patent and licensing status undisclosed	Bregman, H. <i>et al. J. Med. Chem.</i> ; published online Jan. 14, 2013; doi:10.1021/jm301607v Contact: Xin Huang, Amgen Inc., Cambridge, Mass. e-mail: hxin@amgen.com